文献类型：期刊文献

英文题名：Synthesis and Biopharmaceutical Applications of Sugar-Based Polymers: New Advances and Future Prospects

作者：Wang, Jie[1];Wang, Dong[1];Zhang, Yixian[1];Dong, Jian[1]

机构：[1]Shaoxing Univ, Coll Chem & Chem Engn, Shaoxing 312000, Zhejiang, Peoples R China

年份：2021

卷号：7

期号：3

起止页码：963

外文期刊名：ACS BIOMATERIALS SCIENCE & ENGINEERING

收录：SCI-EXPANDED(收录号：WOS:000627588400014)、、EI(收录号：20210709932813)、Scopus(收录号：2-s2.0-85100970015)、WOS

基金：This work was supported by the National Natural Science Foundation of China (21973061 and 21674063).

语种：英文

外文关键词：glycopolymer; glycan; polymerization; targeted drug delivery; ligand-receptor interaction; immunotherapy

外文摘要：The rapid rise in research interest in carbohydrate-based polymers is undoubtedly due to the nontoxic nature of such materials in an in vivo environment and the versatile roles that the polymers can play in cellular functions. Such polymers have served as therapeutic tools for drug delivery, including antigens, proteins, and genes, as well as diagnostic devices. Our focus in the first half of this Review is on synthetic methods based on ring-opening polymerization and enzyme-catalyzed polymerization, along with controlled radical polymerization. In the second half of this Review, sugar-based polymers are discussed on the basis of their remarkable success in competitive receptor binding, as multifunctional nanocarriers of targeting inhibitors for cancer treatment, in genome-editing delivery, in immunotherapy based on endogenous antibody recruitment, and in treatment of respiratory diseases, including influenza A. Particular emphasis is put on the synthesis and biopharmaceutical applications of sugar-based polymers published in the most recent 5 years. A noticeable attribute of carbohydrate-based polymers is that the sugar-receptor interactions can be facilitated by the cooperative effect of multiple sugar units. Their diversified topology and structures will drive the development of new synthetic strategies and bring about important applications, including coronavirus-related drug therapy.